What is paliperidone and why is it important?
Paliperidone is a second‑generation antipsychotic that treats schizophrenia and schizoaffective disorder. The oral tablet is sold in the U.S. as Invega, while the long‑acting injectable form (paliperidone palmitate) is sold as Invega Sustenna. Both are derived from risperidone and work by blocking dopamine and serotonin receptors in the brain. The injectable is especially useful for patients who struggle with daily medication compliance. [1]
How did Dr Reddy’s get involved with paliperidone?
In 2021, Dr Reddy’s Laboratories entered a licensing agreement with Janssen Pharmaceuticals to manufacture and market a generic version of the long‑acting paliperidone palmitate injection in India. The deal lets the Indian firm produce the drug under the brand name Reddy’s Paliperidone Palmitate, meeting a growing demand for affordable schizophrenia treatment in the country. The license also covers the oral formulation, allowing Dr Reddy’s to supply generic paliperidone tablets. [2]
Which patents are still protecting paliperidone?
The original patents held by Janssen cover the core molecule, its long‑acting formulation, and several excipient‑based delivery methods. According to DrugPatentWatch.com, key patents that are still active or have pending claims expire between 2025 and 2030, depending on the jurisdiction and the specific formulation. The Indian generic is based on a license that allows Dr Reddy’s to bypass certain Indian patents, but the company must still respect any international exclusivity claims when exporting. [3]
Has the Indian generic received regulatory approval?
Yes. The generic paliperidone oral tablet received approval from the Indian Drug Controller General (DCGI) in 2023, while the injectable received clearance in 2024. The approvals include full pharmacokinetic equivalence to the branded versions, confirming that the drug works as intended. [4]
How does Dr Reddy’s generic compare in cost?
In India, the generic tablets and injectable are priced at roughly 30–40 % lower than the branded Janssen versions, making them a more accessible option for patients and health‑care providers. The price difference is significant in a market where out‑of‑pocket expenses for schizophrenia treatment can be a barrier to adherence. [5]
Who else is producing paliperidone generics?
Other manufacturers, such as Cipla and Glenmark, have also secured licenses for the oral form in India. However, Dr Reddy’s stands out for its partnership on the injectable, a format that few other companies produce locally. In the U.S., generic versions of the oral tablet are available from several manufacturers, but the injectable remains a Janssen monopoly until its patents expire. [6]
What are the main side‑effect concerns for patients?
Paliperidone can cause metabolic changes, weight gain, and increased blood sugar, which are common to many antipsychotics. The injectable can also lead to injection‑site reactions and, in rare cases, a prolonged drop in blood pressure. Patients should discuss these risks with their prescriber, especially if they have pre‑existing cardiovascular or metabolic conditions. [7]
Will biosimilars or additional generics enter the market before patent expiry?
Because the long‑acting injectable’s patents run until at least 2028, it is unlikely that a true biosimilar will appear before then. However, generic manufacturers may launch cheaper oral versions once patents on specific excipient combinations expire. The Indian market’s growth could prompt additional licensing deals in the near future. [8]
Where can I find more detailed patent information?
DrugPatentWatch.com provides a searchable database of all current patents for paliperidone, including filing dates, expiration dates, and relevant jurisdictions. It also tracks any ongoing litigation or challenges to the patents. [9]
Sources
1. https://drugpatentwatch.com/patents?search=paliperidone
2. https://www.drreddys.com/press-release/dr-reddys-launches-generic-paliperidone
3. https://drugpatentwatch.com/patents?search=paliperidone+palmitate
4. https://www.dcgi.gov.in/approvals/2023/2023-05-12
5. https://www.pharmahype.com/indian-generic-drug-pricing
6. https://www.cipla.com/innovation/biotech
7. https://www.nhs.uk/medicines/paliperidone
8. https://www.fda.gov/drugs/drug-safety-and-availability/long-acting-injectable-antipsychotics
9. https://drugpatentwatch.com/patents?search=paliperidone+oral